Atara Biotherapeutics, Inc.
ATRA
Rank in Stocks
#20577
Founded in 2012 and headquartered in South San Francisco, California, Atara... Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Share Price
$8.18
Last synced: 2026-11-09
Market Cap
$82.11M
Change (1 day)
3.94%
Change (1 year)
-34.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atara Biotherapeutics, Inc. (ATRA)
Category
Healthcare
Operating Margin for Atara Biotherapeutics, Inc. (ATRA)
Operating Margin as of November 2026 TTM: -229.67%
According to Atara Biotherapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -229.67%. At the end of 2025 the company had an operating margin of 29.69%.
Operating Margin history for Atara Biotherapeutics, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -229.67% | -873.56% |
| 2025 | 29.69% | -145.88% |
| 2024 | -64.71% | -97.99% |
| 2023 | -3,219.48% | 629.63% |
| 2022 | -441.25% | -73.64% |
| 2021 | -1,673.85% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.17% |
US
|
|
| -149.01% | -99.35% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 31.23% | -100.14% |
BE
|
|
| 29.35% | -100.13% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Atara Biotherapeutics, Inc.'s operating margin
What is Atara Biotherapeutics, Inc.'s operating margin?
Atara Biotherapeutics, Inc.'s operating margin is -229.67%, as of Nov 2026.
What was Atara Biotherapeutics, Inc.'s operating margin in 2025?
In 2025, Atara Biotherapeutics, Inc.'s operating margin was 29.69%, compared with -64.71% in 2024.
How has Atara Biotherapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Atara Biotherapeutics, Inc.'s operating margin was highest in 2025 (29.69%) and lowest in 2023 (-3,219.48%).
How does Atara Biotherapeutics, Inc.'s operating margin compare with similar companies?
Atara Biotherapeutics, Inc.'s operating margin (-229.67%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.